Michael Lewis is a research scientist in the Stanley Center for Psychiatric Research at the Broad Institute. He focuses on the development of animal models of psychiatric disease, as well as the molecular effects of psychiatric medication. He hopes to bring this knowledge to bear on the next generation of mood-stabilizing and anti-psychotic drugs.
In 2011, Lewis and his fellow researchers at the Stanley Center published a paper describing an important signaling pathway modulated by lithium — a medication used primarily in the treatment of bipolar disorder. The researchers may be able to exploit the signaling pathway to identify a new class of mood-stabilizing drugs.
In 2013, Lewis and colleagues published a paper describing the potential for mood-stabilizing effects of selective histone deacetylase (HDAC) inhibitors in two animal models of psychiatric disease and published a review detailing the potential for HDAC inhibitors to treat schizophrenia and other psychiatric disorders.
Lewis joined the Broad Institute in 2008 after completing a Ph.D. in behavioral neuroscience at Temple University, and conducting postdoctoral research in the same field at Yale University.
Weïwer M, Lewis MC, et al. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia. Future Med Chem. 2013 Sep; 5(13):1491-508. doi: 10.4155/fmc.13.141.
Schroeder FA, Lewis MC, et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS One. 2013 Aug 14; 8(8):e71323. doi: 10.1371/journal.pone.0071323.
Pan JQ, et al. AKT Kinase Activity Is Required for Lithium to Modulate Mood-Related Behaviors in Mice. Neuropsychopharmacology. 2011 Mar 9;36:1397-1411. doi: 10.1038/npp.2011.24.